Bristol-Myers now expects the Celgene deal to close by 2019 end, pushing Celgene’s shares up 3% before the opening bell. Amgen shares, however, fell as some investors worried that the company was shelling out more-than-expected for the drug. The deal for Otezla and certain related assets and liabilities is valued at $11.2 billion, net of the present value of $2.2 billion in future cash tax benefits.

source https://finance.yahoo.com/news/amgen-buy-celgenes-psoriasis-drug-121622595.html?.tsrc=rss